Verily Shrinks Its Scope: Shutters Device Program, Cuts Jobs to Fuel AI Ambitions
Alphabet’s health-science arm, Verily, is undergoing a major pivot—saying goodbye to medical device manufacturing and laying off staff to redirect focus toward artificial intelligence and precision health technologies.
What’s Going On?
-
Devices Program Axed: In a recent internal memo, CEO Stephen Gillett announced the full shutdown of Verily’s medical devices division. Projects like the clinical study smart‑watch, retinal imaging camera, and glucose monitor developed with Dexcom will no longer be supported or manufactured. However, the company will continue honoring existing commitments for devices still in active clinical trials.
-
Job Cuts Implemented: While the number of layoffs was not revealed, a spokesperson framed the move as a deliberate resource reallocation aimed at strengthening Verily’s path to commercial success.
-
Strategic Shift to AI & Data: Verily is refocusing on precision health platforms underpinned by AI and data infrastructure, areas deemed more scalable and aligned with long-term goals. This aligns with broader trends at Alphabet, which has rapidly moved resources toward AI since 2023.
-
Legacy of Innovation Acknowledged: Despite the decision to discontinue device manufacturing, Gillett praised the of the Devices team, noting their work on initiatives like the Dexcom G7 CGM and the Stargazer VNRC trial involving thousands of patients.
-
Ongoing Evolution: This move builds on Verily’s earlier transitions, including the 2023 sale of its insurance subsidiary, Granular, to Elevance Health—a strategic step that freed up resources for AI expansion.
Why It Matters
-
Hardware to Software Pivot: Verily’s shift signals an important industry trend, scaling back on ambitious hardware projects to prioritize AI-driven platforms that drive long-term efficiencies and revenue generation.
-
Cost Realignment & Focus: The cut reflects a broader push within Alphabet to trim “Other Bets” and channel investments into AI, especially as competition from companies like OpenAI and Microsoft intensifies
-
Talent Displacement vs. Opportunity: Layoffs disrupt careers, but Verily’s new direction may create demand for AI-savvy professionals. The shift prioritizes data and health-tech integration over hardware engineering.
-
What’s Next for Verily: The company is doubling down on becoming a tech infrastructure provider for healthcare, positioning itself as a hub for precision health tools and AI platforms, a vision that involves shedding the legacy device arm.